About
ProCore Bio Med is a biotechnology company developing cost-effective solutions with a focus on bone and cartilage regeneration, integrating proprietary scaffolds, growth factors, and stem or progenitor cells. The companys technology platform includes a variety of biomaterials useful for multiple clinical applications, in particular hyaluronic acid-based injectable hydrogels; a set of proprietary growth factors with enhanced activity, selectivity, and stability; and protocols for stem and progenitor cell isolation, expansion, and differentiation. ProCores RegenoGel is a highly stable viscosupplement gel for treating osteoarthritis to preserve joints and regenerate cartilage. RegenoGel is based on the companys proprietary HAProLink, which joins a high-molecular-weight HA with a regenerative fibrinogen matrix. ProCore has been a principal member of the Genesis consortium, the Israeli consortium for stem cell therapy. Procore was acknowledged for its contributions to the consortium, including allowing access to its proprietary set of FGF variants, as well as for its unique stem cell platform and the development of a novel antibody microarray for stem cell characterization.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is ProCore Bio Med's primary focus in biotechnology?
- ProCore Bio Med focuses on developing cost-effective solutions for bone and cartilage regeneration, utilizing proprietary scaffolds, growth factors, and stem or progenitor cells.
- What is ProCore Bio Med's flagship product for treating osteoarthritis?
- ProCore Bio Med's flagship product is RegenoGel, a viscosupplement gel designed to treat osteoarthritis by preserving joints and regenerating cartilage. It is based on the company's proprietary HAProLink technology.
- What is the core technology behind ProCore Bio Med's RegenoGel product?
- RegenoGel is based on ProCore Bio Med's proprietary HAProLink, which combines high-molecular-weight hyaluronic acid (HA) with a regenerative fibrinogen matrix.
- What role did ProCore Bio Med play in the Genesis consortium?
- ProCore Bio Med was a principal member of the Genesis consortium, the Israeli consortium for stem cell therapy. The company contributed by providing access to its proprietary FGF variants, its stem cell platform, and developing a novel antibody microarray for stem cell characterization.
- When was ProCore Bio Med founded?
- ProCore Bio Med was founded in September 2008.
- Where is ProCore Bio Med headquartered?
- ProCore Bio Med is headquartered in Ness Ziona, Israel.
- Who is a key founder of ProCore Bio Med?
- Prof. Avner Yayon is a founder of ProCore Bio Med.
- What are some of the biomaterials included in ProCore Bio Med's technology platform?
- ProCore Bio Med's technology platform includes hyaluronic acid-based injectable hydrogels and a set of proprietary growth factors.